Physiomics plc combines systems biology with cutting edge mathematics to develop models that streamline the drug discovery and development process. Virtual Tumour, the company’s lead service, is used to optimise the dosing and scheduling of oncology drugs in pre-clinical trials, reducing the need for animal experiments. This optimisation also improves the efficacy of combinations in pre-clinical xenografts.
The company is also developing:
(i) Virtual Tumour Clinical, to directly predict optimal regimens for human clinical trials.
(ii) Cardiac tox prediction service, to predict unwanted toxic side effects of drug candidates early on in the drug discovery process.
(iii) Drug combinations database, for researchers and clinicians to rapidly access literature data on pre-clinical and clinical regimens and their effects.
Physiomics has worked with Eli Lilly since 2007 and recently added a further two large pharmaceutical clients. In addition, Physiomics has collaborated with a number of other companies including Bayer Technology Services, Sareum, ValiRx, Cancer Research Technologies and Cyclacel. Fee-for-service, licensing and revenue sharing options are available.